RecruitingNCT05995782
FB418 or placebo: safety of single and repeated doses in healthy adults and older adults
About this title
Read the official source — NCT05995782Medication studyAges 19+South KoreaSchizophrenia
Understand this study
Who could participate?
This study is for healthy volunteers. Listed age limits: from 19 years. Other eligibility criteria apply.
- Listed locations
- SeoulSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 20, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 64
- Sponsor
- 1ST Biotherapeutics, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- South Korea
- Age range
- Over 19 Years
- Official registry ID
- NCT05995782
- Official title
Show the full official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral FB418 in Healthy Adult Subjects and Healthy Elderly Subjects
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Seoul
Questions about this study
Who is behind this study?
The study sponsor is 1ST Biotherapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including FB418.
Who can participate?
This study is for healthy volunteers. Listed age limits: from 19 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
